4 Report Package: "Drug the Undruggable" Technologies Bundle - Four Full Reports for the Price of Two
12 mars 2021 04h13 HE
|
Research and Markets
Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Report Package: "Drug the Undruggable" Technologies" report has been added to ResearchAndMarkets.com's offering. This report package includes four...
Arvinas to Participate in Upcoming Virtual Investor Conferences
10 mars 2021 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences
09 mars 2021 07h30 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur...
Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock
02 mars 2021 16h15 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has...
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
01 mars 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update
16 févr. 2021 16h01 HE
|
Nurix Therapeutics, Inc.
First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies Three additional wholly owned programs expected to enter clinical...
Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
08 févr. 2021 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies
07 janv. 2021 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of...
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
15 déc. 2020 20h35 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...
Arvinas, Inc. Announces Proposed Offering of Common Stock
14 déc. 2020 16h06 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...